Differences in hormone therapy for patients with advanced metastatic prostate cancer

Bookmark and Share
Published: 9 May 2019
Views: 610
Prof Axel Merseburger - University Hospital Schleswig-Holstein, Lübeck, Germany

Prof Axel Merseburger speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the differences between the multiple forms of androgen deprivation therapy (ADT) that are available.

Prof Merseburger explains the advantages and disadvantages associated with the use of LHRH agonists versus LHRH antagonists and how these can be applied to the clinic.

He also mentions the PRONOUNCE trial, which aims to assess the occurrence of cardiovascular events among patients receiving ADT.